Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...

The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its ...

(Bloomberg) -- Sanofi profit rose on demand for seasonal vaccines and further growth in its blockbuster skin and asthma therapy Dupixent. Earnings per share excluding some items reached €2.86 ($ ...

Sanofi SAN0.01%increase; green up pointing triangle reported third-quarter earnings and sales that beat analysts’ expectations, boosted by earlier-than-anticipated deliveries of flu and ...

Note: Due to a pricing disagreement with the French government, Sanofi’s HD flu vaccine Efluelda, intended for people older than 65 years, will not be available this year. (See: Withdrawal of ...

A collaboration with Sanofi offers flexibility and potential growth, allowing Novavax to focus on developing a COVID-19/influenza combination (CIC) and seasonal influenza vaccines. Despite ...

Margaret Haugh (MediCom Consult) provided translation and editing services, which was funded by Sanofi Pasteur MSD. Box 1. Current nomenclature for influenza viruses (WHO 1980). The formal ...

The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines, the company said on Monday.